Joseph A. Bauer leads the charge here. He works for Nitric Oxide Services and the Cleveland Clinic’s Taussig Cancer Center. His team is looking at something weird. They are tweaking vitamin B12.
Specifically they are using nitrosylcobalamin. Shortened to NO-Cbl. This modified form releases nitric oxide. The goal? See if it can smash through the blood-brain barrier. See if it hides inside glioblastoma tumors.
Glioblastoma multiforme. GBM. It is a killer. Brutal treatment resistance. You cut it out. You burn it with radiation. You poison it with chemo. Patients usually survive less than 15 months.
Why?
The blood-brain barrier protects the brain from drugs just as much as it does from infections. Most therapies bounce right off.
Testing the Theory
So Bauer’s team put NO-Cbl through the wringer.
They tested it against the NCI-60 panel. That’s a big library of human tumor cell lines. They ran rats through it too. Pharmacokinetic studies to see where the compound goes. Then they looked at combos. What happens if you mix NO-Cbl with current treatments in human glioblastoma cells?
The results? Antitumor activity popped up across many cancer types.
CNS origin tumors were moderately sensitive. Good sign. Not great. But a sign.
Hiding in the Tumor
This part is interesting.
Animal experiments showed NO-Cbl crossing that barrier. It didn’t just enter the brain. It preferred the glioblastoma tissue.
Selective accumulation.
It hung around the tumor site too. Nitrate levels stayed high in the tumor tissue for at least 24 hours post-treatment. Normal tissues? Their levels dropped fast.
It’s like the compound is taking a permanent vacation inside the bad cells. Delivered nitric oxide right into the microenvironment.
Figures 2 and 3 in the study back this up. Pages 3-4. You see sustained cobalamin metabolites in the tumor compared to other organs.
It works better together.
Laboratory work used U87 and D54 cell lines. The researchers mixed NO-Cbl with TRAIL or temozolomime.
Standard care drugs. Alone they do what they can. Added together? Suppression of tumor growth spiked. Much stronger than any single drug alone. Synergy. Real synergistic interactions across doses.
As the authors put it:
This pilot study demonstrates that NO-CBl crosses the BBB accumulates selectively in brain tumor tissue and synergizes with established and experimental Glioblastoma Therapies.
Fighting Back Against Resistance
GBM fights back.
Tumors develop mechanisms to survive. NO-Cbl might jam those gears.
Previous papers showed it activates caspase-8. That triggers apoptosis. Cell suicide. It suppresses NF-kB. A survival signal. And it strengthens TRAIL receptors via S-nitrosylation.
All together it makes the tumor cells more vulnerable. Even ones that have already shrugged off temozolomide therapy.
But hold up.
This is early stuff. Pilot translational study. Do not call the neurosurgeon yet.
More work needs to be done. Orthotopic validation is next. Optimizing dosing. Tracking nitric oxide longer. Digging into the mechanics with more CNS models.
Still the evidence points somewhere new. A cobalamin nitric oxide donor that penetrates the barrier and targets tumors selectively. It could change how we think about drug delivery. Or resistance.
One of the toughest cancers in neuro-oncology might finally have a chink in its armor. Maybe.
